Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Research & Development Clinical Trials Infectious Diseases

Plazomicin’s US Debut Pencilled In For 2018, Achaogen Now Searching For Ex-US Partner

Executive Summary

Top-line results from the pivotal Phase III EPIC study, and the smaller CARE study in patients with serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) pathogens, should allow Achaogen to find an ex-US marketing partner and submit a US marketing application in 2017 for its potential new antibacterial, plazomicin, that could address a growing market opportunity in multidrug resistant infections.

Table

View full table

Related Content

Scrip
Scrip

Topics

Related Companies

Tags:
Research & Development Clinical Trials Infectious Diseases
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

SC097876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By